Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6406713 | LEADIANT BIOSCI INC | Methods of preparing low-toxicity drug-lipid complexes |
Jun, 2019
(4 years ago) |
Drugs and Companies using AMPHOTERICIN B ingredient
Market Authorisation Date: 20 November, 1995
Treatment: NA
Dosage: INJECTABLE, LIPID COMPLEX;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6743798 | BAYER HLTHCARE | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-724) | Feb 26, 2019 |
Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
New Indication(I-630) | Oct 29, 2013 |
New Indication(I-655) | Jul 20, 2015 |
New Indication(I-650) | Apr 26, 2015 |
Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
Pediatric Exclusivity(PED) | Oct 26, 2015 |
New Indication(I-638) | May 05, 2014 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5665772 | NOVARTIS PHARM | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-169) | Apr 10, 2025 |
New Indication(I-773) | Apr 10, 2021 |
Pediatric Exclusivity(PED) | Apr 29, 2014 |
Orphan Drug Exclusivity(ODE) | Oct 29, 2017 |
New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
New Indication(I-630) | Oct 29, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 29 April, 2017
Market Authorisation Date: 29 August, 2012
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5852195 | BOEHRINGER INGELHEIM | Pyranone compounds useful to treat retroviral infections |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Dec 23, 2011 |
Drugs and Companies using TIPRANAVIR ingredient
Market Authorisation Date: 23 June, 2008
Treatment: NA
Dosage: SOLUTION;ORAL; CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6780877 | BAUSCH AND LOMB INC | Acid addition salt of optically active piperidine compound and process for preparing the same |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 08, 2014 |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
NCE-1 date: 08 September, 2013
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(4 years ago) | |
US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-848) | Nov 05, 2023 |
M(M-283) | May 09, 2025 |
Pediatric Exclusivity(PED) | Nov 09, 2025 |
New Indication(I-851) | May 28, 2023 |
New Strength(NS) | Sep 03, 2018 |
New Indication(I-714) | Sep 03, 2018 |
New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction; Treatment of thrombotic stroke
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7067522 | GILEAD SCIENCES INC | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Dec 13, 2016 |
New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5998402 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
Apr, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
New Product(NP) | Oct 03, 2016 |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7067522 | JANSSEN PRODS | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Aug 26, 2018 |
M(M-223) | Feb 01, 2021 |
New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6413980 | BRISTOL MYERS SQUIBB | Nitrogen containing heterobicycles as factor Xa inhibitors |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-690) | Aug 21, 2017 |
New Indication(I-661) | Aug 21, 2017 |
New Indication(I-691) | Aug 21, 2017 |
New Indication(I-681) | Mar 03, 2017 |
New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 28 December, 2012
Treatment: Treatment of deep vein thrombosis (dvt)
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-186) | May 02, 2025 |
New Dosing Schedule(D-155) | Feb 01, 2019 |
New Patient Population(NPP) | Apr 03, 2021 |
Pediatric Exclusivity(PED) | Oct 03, 2021 |
New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
New Dosing Schedule(D-128) | Nov 12, 2013 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Treatment: Prevention of nausea and vomiting associated with hec and mec in adult and pediatric patients
Dosage: POWDER;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-239) | Dec 12, 2021 |
Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
M(M-241) | Jul 24, 2022 |
M(M-263) | Jul 23, 2023 |
Orphan Drug Exclusivity(ODE) | Nov 02, 2012 |
New Indication(I-665) | Jan 23, 2016 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 02 November, 2005
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6803376 | LG CHEM LTD | Method of use of quinolone compounds against pneumococcal and haemophilus bacteria |
Sep, 2019
(4 years ago) |
Drugs and Companies using GEMIFLOXACIN MESYLATE ingredient
Market Authorisation Date: 04 April, 2003
Treatment: Use of quinolone compounds against pneumococcal pathogenic bacteria
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5648333 | TAKEDA PHARMS USA | Peptides having bradykinin antagonist action |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-14) | Aug 25, 2018 |
New Chemical Entity Exclusivity(NCE) | Aug 25, 2016 |
Orphan Drug Exclusivity(ODE) | Aug 25, 2018 |
Drugs and Companies using ICATIBANT ACETATE ingredient
NCE-1 date: 26 August, 2015
Market Authorisation Date: 25 August, 2011
Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Strength(NS) | May 11, 2021 |
New Patient Population(NPP) | May 11, 2021 |
Pediatric Exclusivity(PED) | Nov 11, 2021 |
M(M-106) | Jul 20, 2014 |
New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(4 years ago) |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Treatment: A method for treating a tumor disease
Dosage: CAPSULE;ORAL; TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8003789 | JANSSEN R AND D | HIV replication inhibiting pyrimidines |
Nov, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Jan 16, 2022 |
New Patient Population(NPP) | Mar 26, 2015 |
New Chemical Entity Exclusivity(NCE) | Jan 18, 2013 |
Drugs and Companies using ETRAVIRINE ingredient
NCE-1 date: 16 January, 2021
Market Authorisation Date: 26 March, 2012
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6465504 | NOVARTIS PHARMS CORP | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-241) | Jul 24, 2022 |
Orphan Drug Exclusivity(ODE) | Jan 23, 2020 |
M(M-239) | Dec 12, 2021 |
Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6465504 | NOVARTIS | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
Apr, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-241) | Jul 24, 2022 |
M(M-239) | Dec 12, 2021 |
M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 18 May, 2017
Treatment: NA
Dosage: GRANULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7067522 | VIIV HLTHCARE | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-117) | May 18, 2015 |
M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7655637 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) | |
US6642210 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(4 years ago) | |
USRE47351 | ASTELLAS | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun, 2019
(4 years ago) | |
US7144872 | ASTELLAS | N-pyrazole A2A receptor agonists |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-194) | Jan 17, 2020 |
New Chemical Entity Exclusivity(NCE) | Apr 10, 2013 |
Drugs and Companies using REGADENOSON ingredient
NCE-1 date: 10 April, 2012
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6514953 | VIIV HLTHCARE | Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Oct 27, 2015 |
New Patient Population(NPP) | Apr 27, 2015 |
Drugs and Companies using FOSAMPRENAVIR CALCIUM ingredient
Market Authorisation Date: 20 October, 2003
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5686060 | BRACCO | Stable microbubble suspensions comprising saturated phospholipids for ultrasound echography |
Nov, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-728) | Mar 31, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
New Patient Population(NPP) | Nov 13, 2022 |
Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: FOR SUSPENSION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Pediatric Exclusivity(PED) | Jun 20, 2023 |
New Indication(I-821) | Dec 20, 2022 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6288082 | PUMA BIOTECH | Substituted 3-cyanoquinolines |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-182) | Jun 28, 2024 |
New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
New Indication(I-823) | Feb 25, 2023 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 31, 2024 |
Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
New Indication(I-881) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 25 November, 2013
Treatment: Prophylaxis of invasive aspergillus and candida infections
Dosage: TABLET, DELAYED RELEASE;ORAL; SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
Dosage: SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7067522 | GILEAD SCIENCES INC | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
M(M-207) | Aug 21, 2020 |
M(M-206) | Aug 21, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 01 March, 2016
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6429210 | SANOFI AVENTIS US | Polymorphic clopidogrel hydrogenesulphate form |
Jun, 2019
(4 years ago) | |
US6504030 | SANOFI AVENTIS US | Polymorphic form of clopidogrel hydrogen sulphate |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | May 06, 2014 |
Pediatric Exclusivity(PED) | Nov 06, 2014 |
Drugs and Companies using CLOPIDOGREL BISULFATE ingredient
Market Authorisation Date: 17 November, 1997
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6503745 | BIOCRYST | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | Sep 20, 2020 |
New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
New Indication(I-706) | Feb 17, 2018 |
New Indication(I-796) | May 28, 2022 |
New Indication(I-797) | May 28, 2022 |
Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
New Indication(I-672) | Jun 05, 2016 |
Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
New Strength(NS) | Jun 05, 2016 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: NA
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6034239 | TAKEDA PHARMS USA | Tricyclic compounds, their production and use |
Jul, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-82) | Oct 20, 2011 |
Drugs and Companies using RAMELTEON ingredient
Market Authorisation Date: 22 July, 2005
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6586430 | VIIV HLTHCARE | CCR5 modulators |
Dec, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population(NPP) | May 28, 2013 |
New Strength(NS) | Nov 04, 2019 |
New Chemical Entity Exclusivity(NCE) | Aug 06, 2012 |
Drugs and Companies using MARAVIROC ingredient
NCE-1 date: 07 August, 2011
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: TABLET;ORAL; SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5686411 | ASTRAZENECA AB | Amylin agonist peptides and uses therefor |
Mar, 2019
(5 years ago) |
Drugs and Companies using PRAMLINTIDE ACETATE ingredient
Market Authorisation Date: 25 September, 2007
Treatment: Treatment of diabetes with an amylin agonist, including with insulin
Dosage: INJECTABLE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7842687 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) | |
USRE45128 | TEVA PHARMS INTL | Cephalotaxane derivatives and their processes of preparation and purification |
Mar, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with leukemia including chronic myeloid/myelogenous leukemia (cml); Treatment of leukemia
Dosage: POWDER;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE44768 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) | |
US5362718 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-61) | May 30, 2015 |
M(M-92) | Jul 09, 2013 |
Orphan Drug Exclusivity(ODE) | May 30, 2014 |
M(M-91) | Apr 26, 2013 |
Pediatric Exclusivity(PED) | Jan 09, 2014 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-861) | Jun 17, 2024 |
Pediatric Exclusivity(PED) | Dec 17, 2024 |
New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) | |
US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(5 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-235) | Dec 06, 2021 |
New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
New Indication(I-620) | Jan 29, 2013 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Treatment: Treatment of patients with breast cancer whose tumors overexpress the her2 receptor
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5614520 | TAKEDA PHARMS USA | 2-arylthiazole derivatives and pharmaceutical composition thereof |
Mar, 2019
(5 years ago) | |
US6225474 | TAKEDA PHARMS USA | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
Jun, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-205) | Aug 15, 2020 |
New Chemical Entity Exclusivity(NCE) | Feb 13, 2014 |
Drugs and Companies using FEBUXOSTAT ingredient
NCE-1 date: 13 February, 2013
Market Authorisation Date: 13 February, 2009
Treatment: Chronic management of hyperuricemia in patients with gout. not recommended for the treatment of asymptomatic hyperuricemia
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with euvolemic hyponatremia
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with euvolemic hyponatremia
Dosage: INJECTABLE;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5532241 | ABBVIE | Piperidines and piperazines |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosing Schedule(D-146) | Mar 16, 2018 |
M(M-254) | Jan 31, 2023 |
Pediatric Exclusivity(PED) | Jul 31, 2023 |
New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Apr 20, 2013 |
New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
New Indication(I-668) | Feb 15, 2016 |
Pediatric Exclusivity(PED) | Oct 20, 2013 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 30 September, 2013
Market Authorisation Date: 20 April, 2010
Treatment: Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6333045 | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Aug, 2019
(4 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | May 18, 2013 |
Drugs and Companies using GATIFLOXACIN ingredient
Market Authorisation Date: 18 May, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5795965 | NA | Reshaped human to human interleukin-6 receptor |
Apr, 2019
(5 years ago) |
Ingredients: TOCILIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5681818 | NA | Therapeutic uses of human somatomedin carrier proteins |
May, 2019
(4 years ago) |
Ingredients: MECASERMIN RINFABATE [RDNA ORIGINAL INJECTION]
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5750497 | NA | Acylated insulin |
Jun, 2019
(4 years ago) |
Ingredients: INSULIN DETEMIR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5851795 | NA | Soluble CTLA4 molecules and uses thereof |
Oct, 2019
(4 years ago) |
Ingredients: ABATACEPT
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5693323 | NA | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
Dec, 2019
(4 years ago) |
Ingredients: MEPOLIZUMAB